
CLAIMS


What is claimed is:


1. A compound of Formula I





I

wherein

(i) R_1 and R_3 are independently hydrogen; and R_2 is  ; or

(ii) R_1 is independently hydrogen; R_3 is methyl; and R_2 is  or

 ; or

(iii) wherein R_2 and R_3 are independently hydrogen; and R_1 is  .

2. A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmacological acceptable carrier.

3. A pharmaceutical composition for increasing Src homology-2 containing protein tyrosine phosphatase-1 (SHP-1) expression in a cell, comprising a compound as defined in claim 1 and a pharmacological acceptable carrier.

4. A pharmaceutical composition for treating a disease or condition characterized by decreased Src homology-2 containing protein tyrosine phosphatase-1 (SHP-1), comprising a compound as defined in claim 1 and a pharmacological acceptable carrier.

5. A method for increasing Src homology-2 containing protein tyrosine phosphatase-1 (SHP-1) expression in a cell *in vitro*, comprising contacting the cell with an effective amount of a compound as defined in claim 1 or a pharmaceutical composition of claim 2.


6. Use of a compound as defined in claim 1 for manufacture of a medicament for treating a disease or condition characterized by decreased Src homology-2 containing protein tyrosine phosphatase-1 (SHP-1) expression, wherein the disease or condition characterized by decreased SHP-1 expression is cancer and osteoporosis.

7. Use of claim 6, wherein the cancer is hepatocellular carcinoma (e.g. hepatocellular carcinoma, leukemia, lung cancer, breast cancer, renal cancer, thyroid cancer, colon cancer, head and neck cancer.

CLAIMS


What is claimed is:

1. A compound which is represented by Formula I




I


wherein R_1, and R_3 are independently hydrogen, and R_2 is




,




,




,




,



,


;


or

wherein R_1 is independently hydrogen; R_3 is methyl; and R_2 is



or


; or


wherein R_2 and R_3 are independently hydrogen; and R_1 is



2. A compound is



3. A compound is



4. A pharmaceutical composition comprising a compound as defined in any of claims **1** to **3** and a pharmacological acceptable carrier.

5. A pharmaceutical composition for increasing Src homology-2 containing protein tyrosine phosphatase-1 (SHP-1) expression in a cell, comprising a compound as defined in any of claims **1** to **3** and a pharmacological acceptable carrier.

6. A pharmaceutical composition for treating a disease or condition characterized by decreased Src homology-2 containing protein tyrosine phosphatase-1 (SHP-1), comprising a compound as defined in any of claims **1** to **3** and a pharmacological acceptable carrier, wherein the disease or condition is a cancer or osteoporosis.

7. The pharmaceutical composition of claim **6**, wherein the cancer is hepatocellular carcinoma, leukemia, lung cancer, breast cancer, renal cancer, thyroid cancer, colon cancer, head or neck cancer.

8. A method for increasing Src homology-2 containing protein tyrosine phosphatase-1 (SHP-1) expression in a cell, comprising contacting the cell with an effective amount of a compound as defined in any of claims **1** to **3** or a pharmaceutical composition of claim **4**.